Skip to main content
Clinical Trials/NCT02503267
NCT02503267
Unknown
Not Applicable

"Incidence and Consequences of Disorders of Glycosylation in Patients With Conotruncal and Septal Heart Defects" (CARDIoG)

Hospital Universitari Vall d'Hebron Research Institute1 site in 1 country300 target enrollmentJuly 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Congenital Heart Diseases
Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Enrollment
300
Locations
1
Primary Endpoint
Disorders of glycosylation
Last Updated
9 years ago

Overview

Brief Summary

The objective of the study is to investigate congenital disorders of glycosylation in congenital heart diseases without a clear molecular or genetic basis.

Detailed Description

Congenital disorders of glycosylation (CDG) are a family of inherited disorders caused by defects in the synthesis of glycans, glycoproteins or other glycoconjugates. Congenital disorders of glycosylation (CDG) are a family of inherited disorders caused by defects in the synthesis of glycans, glycoproteins or other glycoconjugates. Glycosylation of proteins is crucial for a proper organ morphogenesis and for an appropriate coagulation system functioning. The neurological system is commonly affected in this type of disorders but cases of CDG with normal neurological development have been recently described. The group of Experimental Hematology and Clinic Oncology of the University of Murcia (Spain) recently described a rare disorder of glycosylation (ALG12-CDG) as the cause of antithrombin deficiency in a patient of 19 years with a history of repaired ventricular septal defect. On the other hand, population studies have shown an increased incidence of thromboembolic events in patients with congenital heart disease when compared to the general population. The identified genetic defects involved in the development of congenital heart diseases have variable or incomplete penetrance and in most cases the molecular basis is completely unknown. The investigators postulate that a CDG might be behind the development of some forms of congenital heart disease and contribute to the greater prevalence of thromboembolic events in this patient population.

Registry
clinicaltrials.gov
Start Date
July 2015
End Date
June 2017
Last Updated
9 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Adult with a congenital heart disease with most probability to present a congenital disorder of glycosylation of proteins

Exclusion Criteria

  • Denial of informed consent.

Outcomes

Primary Outcomes

Disorders of glycosylation

Time Frame: 1 year

Secondary Outcomes

  • Incidence of antithrombin deficiency(1 year)

Study Sites (1)

Loading locations...

Similar Trials